RecruitingPhase 1Phase 2NCT06697197
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
A Phase 1/2 Study of BMS-986482 as Monotherapy or Combination Therapy in Participants With Advanced Solid Tumors
Sponsor
Bristol-Myers Squibb
Enrollment
413 participants
Start Date
Feb 17, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to test the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- All participants must have a histologically or cytologically confirmed, advanced, unresectable/metastatic, solid malignancy measurable by RECIST v1.1, and have received, be refractory to, ineligible for, intolerant of, or refused existing therapy(ies) known to provide clinical benefit for the condition of the participant.
- Participant must be ≥ 18 years or the legal age of consent in the jurisdiction in which the study is taking place, inclusive, at the time of signing the ICF.
Exclusion Criteria2
- History of life threatening immune mediated toxicity related to prior T-cell agonist or checkpoint inhibitor therapy, except those that are unlikely to re-occur with standard countermeasures.
- Any significant acute or chronic medical illness which would interfere with study intervention or follow-up in the opinion of the investigator.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGBMS-986482
Specified dose on specified days
DRUGNivolumab and rHuPH20
Specified dose on specified days
DRUGNivolumab/relatlimab/rHuPH20
Specified dose on specified days
DRUGBevacizumab
Specified dose on specified days
Locations(21)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06697197
Related Trials
NK521 in the Treatment of Malignant Ascites Associated With Advanced Solid Tumors
NCT075614371 location
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
NCT0641368011 locations
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
NCT042224132 locations
A Study of MGC028 in Participants With Advanced Solid Tumors
NCT067232367 locations
A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer
NCT074390941 location